Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.
Identifieur interne : 003173 ( Main/Merge ); précédent : 003172; suivant : 003174Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.
Auteurs : Matthias Liniger [Suisse] ; Armando Zuniga ; Azaibi Tamin ; Teldja N. Azzouz-Morin ; Marlyse Knuchel ; Rene R. Marty ; Marian Wiegand ; Sara Weibel ; David Kelvin ; Paul A. Rota ; Hussein Y. NaimSource :
- Vaccine [ 0264-410X ] ; 2008.
Descripteurs français
- KwdFr :
- Animal génétiquement modifié, Animaux, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (génétique), Glycoprotéines membranaires (immunologie), Protéines de l'enveloppe virale (immunologie), Protéines nucléocapside (génétique), Souris, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Tests de neutralisation, Vaccin contre la rougeole (administration et posologie), Vaccin contre la rougeole (génétique), Vaccin contre la rougeole (immunologie), Vaccins antiviraux (), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (génétique), Vaccins antiviraux (immunologie), Vaccins synthétiques (administration et posologie), Vaccins synthétiques (immunologie), Vecteurs génétiques (), Virus de la rougeole (métabolisme), Virus de la rougeole (physiologie), Virus du SRAS (génétique), Virus du SRAS (immunologie), Virus du SRAS (métabolisme).
- MESH :
- administration et posologie : Vaccin contre la rougeole, Vaccins antiviraux, Vaccins synthétiques.
- génétique : Glycoprotéines membranaires, Protéines nucléocapside, Vaccin contre la rougeole, Vaccins antiviraux, Virus du SRAS.
- immunologie : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Syndrome respiratoire aigu sévère, Vaccin contre la rougeole, Vaccins antiviraux, Vaccins synthétiques, Virus du SRAS.
- métabolisme : Virus de la rougeole, Virus du SRAS.
- physiologie : Virus de la rougeole.
- Animal génétiquement modifié, Animaux, Glycoprotéine de spicule des coronavirus, Souris, Syndrome respiratoire aigu sévère, Tests de neutralisation, Vaccins antiviraux, Vecteurs génétiques.
English descriptors
- KwdEn :
- Animals, Animals, Genetically Modified, Genetic Vectors (chemistry), Measles Vaccine (administration & dosage), Measles Vaccine (genetics), Measles Vaccine (immunology), Measles virus (metabolism), Measles virus (physiology), Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Mice, Neutralization Tests, Nucleocapsid Proteins (genetics), SARS Virus (genetics), SARS Virus (immunology), SARS Virus (metabolism), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology), Viral Envelope Proteins (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (chemistry), Viral Vaccines (genetics), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Measles Vaccine, Vaccines, Synthetic, Viral Vaccines.
- chemistry : Genetic Vectors, Viral Vaccines.
- chemical , genetics : Measles Vaccine, Membrane Glycoproteins, Nucleocapsid Proteins, SARS Virus, Viral Vaccines.
- chemical , immunology : Measles Vaccine, Membrane Glycoproteins, SARS Virus, Severe Acute Respiratory Syndrome, Vaccines, Synthetic, Viral Envelope Proteins, Viral Vaccines.
- metabolism : Measles virus, SARS Virus.
- physiology : Measles virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- Animals, Animals, Genetically Modified, Mice, Neutralization Tests, Spike Glycoprotein, Coronavirus.
Abstract
Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) or nucleocapsid protein (N) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) were generated (rMV-S and rMV-N). Both recombinant viruses stably expressed the corresponding SARS-CoV proteins, grew to similar end titres as the parental strain and induced high antibody titres against MV and the vectored SARS-CoV antigens (S and N) in transgenic mice susceptible to measles infection. The antibodies induced by rMV-S had a high neutralising effect on SARS-CoV as well as on MV. Moreover, significant N-specific cellular immune responses were measured by IFN-gamma ELISPOT assays. The pre-existence of anti-MV antibodies induced by the initial immunisation dose did not inhibit boost of anti-S and anti-N antibodies. Immunisations comprising a mixture of rMV-S and rMV-N induced immune responses similar in magnitude to that of vaccine components administered separately. These data support the suitability of MV as a bivalent candidate vaccine vector against MV and emerging viruses such as SARS-CoV.
DOI: 10.1016/j.vaccine.2008.01.057
PubMed: 18346823
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001B88
- to stream PubMed, to step Curation: 001B88
- to stream PubMed, to step Checkpoint: 001B09
- to stream Ncbi, to step Merge: 001C04
- to stream Ncbi, to step Curation: 001C04
- to stream Ncbi, to step Checkpoint: 001C04
Links to Exploration step
pubmed:18346823Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.</title><author><name sortKey="Liniger, Matthias" sort="Liniger, Matthias" uniqKey="Liniger M" first="Matthias" last="Liniger">Matthias Liniger</name><affiliation wicri:level="1"><nlm:affiliation>Berna Biotech (a Crucell Company), Rehhagstrasse 79, CH-3018 Bern, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Berna Biotech (a Crucell Company), Rehhagstrasse 79, CH-3018 Bern</wicri:regionArea><wicri:noRegion>CH-3018 Bern</wicri:noRegion></affiliation></author><author><name sortKey="Zuniga, Armando" sort="Zuniga, Armando" uniqKey="Zuniga A" first="Armando" last="Zuniga">Armando Zuniga</name></author><author><name sortKey="Tamin, Azaibi" sort="Tamin, Azaibi" uniqKey="Tamin A" first="Azaibi" last="Tamin">Azaibi Tamin</name></author><author><name sortKey="Azzouz Morin, Teldja N" sort="Azzouz Morin, Teldja N" uniqKey="Azzouz Morin T" first="Teldja N" last="Azzouz-Morin">Teldja N. Azzouz-Morin</name></author><author><name sortKey="Knuchel, Marlyse" sort="Knuchel, Marlyse" uniqKey="Knuchel M" first="Marlyse" last="Knuchel">Marlyse Knuchel</name></author><author><name sortKey="Marty, Rene R" sort="Marty, Rene R" uniqKey="Marty R" first="Rene R" last="Marty">Rene R. Marty</name></author><author><name sortKey="Wiegand, Marian" sort="Wiegand, Marian" uniqKey="Wiegand M" first="Marian" last="Wiegand">Marian Wiegand</name></author><author><name sortKey="Weibel, Sara" sort="Weibel, Sara" uniqKey="Weibel S" first="Sara" last="Weibel">Sara Weibel</name></author><author><name sortKey="Kelvin, David" sort="Kelvin, David" uniqKey="Kelvin D" first="David" last="Kelvin">David Kelvin</name></author><author><name sortKey="Rota, Paul A" sort="Rota, Paul A" uniqKey="Rota P" first="Paul A" last="Rota">Paul A. Rota</name></author><author><name sortKey="Naim, Hussein Y" sort="Naim, Hussein Y" uniqKey="Naim H" first="Hussein Y" last="Naim">Hussein Y. Naim</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18346823</idno><idno type="pmid">18346823</idno><idno type="doi">10.1016/j.vaccine.2008.01.057</idno><idno type="wicri:Area/PubMed/Corpus">001B88</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B88</idno><idno type="wicri:Area/PubMed/Curation">001B88</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B88</idno><idno type="wicri:Area/PubMed/Checkpoint">001B09</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B09</idno><idno type="wicri:Area/Ncbi/Merge">001C04</idno><idno type="wicri:Area/Ncbi/Curation">001C04</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C04</idno><idno type="wicri:doubleKey">0264-410X:2008:Liniger M:induction:of:neutralising</idno><idno type="wicri:Area/Main/Merge">003173</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.</title><author><name sortKey="Liniger, Matthias" sort="Liniger, Matthias" uniqKey="Liniger M" first="Matthias" last="Liniger">Matthias Liniger</name><affiliation wicri:level="1"><nlm:affiliation>Berna Biotech (a Crucell Company), Rehhagstrasse 79, CH-3018 Bern, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Berna Biotech (a Crucell Company), Rehhagstrasse 79, CH-3018 Bern</wicri:regionArea><wicri:noRegion>CH-3018 Bern</wicri:noRegion></affiliation></author><author><name sortKey="Zuniga, Armando" sort="Zuniga, Armando" uniqKey="Zuniga A" first="Armando" last="Zuniga">Armando Zuniga</name></author><author><name sortKey="Tamin, Azaibi" sort="Tamin, Azaibi" uniqKey="Tamin A" first="Azaibi" last="Tamin">Azaibi Tamin</name></author><author><name sortKey="Azzouz Morin, Teldja N" sort="Azzouz Morin, Teldja N" uniqKey="Azzouz Morin T" first="Teldja N" last="Azzouz-Morin">Teldja N. Azzouz-Morin</name></author><author><name sortKey="Knuchel, Marlyse" sort="Knuchel, Marlyse" uniqKey="Knuchel M" first="Marlyse" last="Knuchel">Marlyse Knuchel</name></author><author><name sortKey="Marty, Rene R" sort="Marty, Rene R" uniqKey="Marty R" first="Rene R" last="Marty">Rene R. Marty</name></author><author><name sortKey="Wiegand, Marian" sort="Wiegand, Marian" uniqKey="Wiegand M" first="Marian" last="Wiegand">Marian Wiegand</name></author><author><name sortKey="Weibel, Sara" sort="Weibel, Sara" uniqKey="Weibel S" first="Sara" last="Weibel">Sara Weibel</name></author><author><name sortKey="Kelvin, David" sort="Kelvin, David" uniqKey="Kelvin D" first="David" last="Kelvin">David Kelvin</name></author><author><name sortKey="Rota, Paul A" sort="Rota, Paul A" uniqKey="Rota P" first="Paul A" last="Rota">Paul A. Rota</name></author><author><name sortKey="Naim, Hussein Y" sort="Naim, Hussein Y" uniqKey="Naim H" first="Hussein Y" last="Naim">Hussein Y. Naim</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Animals, Genetically Modified</term><term>Genetic Vectors (chemistry)</term><term>Measles Vaccine (administration & dosage)</term><term>Measles Vaccine (genetics)</term><term>Measles Vaccine (immunology)</term><term>Measles virus (metabolism)</term><term>Measles virus (physiology)</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Neutralization Tests</term><term>Nucleocapsid Proteins (genetics)</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>SARS Virus (metabolism)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, Synthetic (administration & dosage)</term><term>Vaccines, Synthetic (immunology)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (chemistry)</term><term>Viral Vaccines (genetics)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animal génétiquement modifié</term><term>Animaux</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (génétique)</term><term>Glycoprotéines membranaires (immunologie)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Protéines nucléocapside (génétique)</term><term>Souris</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Tests de neutralisation</term><term>Vaccin contre la rougeole (administration et posologie)</term><term>Vaccin contre la rougeole (génétique)</term><term>Vaccin contre la rougeole (immunologie)</term><term>Vaccins antiviraux ()</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (génétique)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins synthétiques (administration et posologie)</term><term>Vaccins synthétiques (immunologie)</term><term>Vecteurs génétiques ()</term><term>Virus de la rougeole (métabolisme)</term><term>Virus de la rougeole (physiologie)</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Measles Vaccine</term><term>Vaccines, Synthetic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccin contre la rougeole</term><term>Vaccins antiviraux</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Genetic Vectors</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Measles Vaccine</term><term>Membrane Glycoproteins</term><term>Nucleocapsid Proteins</term><term>SARS Virus</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines nucléocapside</term><term>Vaccin contre la rougeole</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccin contre la rougeole</term><term>Vaccins antiviraux</term><term>Vaccins synthétiques</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Measles Vaccine</term><term>Membrane Glycoproteins</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Vaccines, Synthetic</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Measles virus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Virus de la rougeole</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus de la rougeole</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Measles virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Animals, Genetically Modified</term><term>Mice</term><term>Neutralization Tests</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animal génétiquement modifié</term><term>Animaux</term><term>Glycoprotéine de spicule des coronavirus</term><term>Souris</term><term>Syndrome respiratoire aigu sévère</term><term>Tests de neutralisation</term><term>Vaccins antiviraux</term><term>Vecteurs génétiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) or nucleocapsid protein (N) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) were generated (rMV-S and rMV-N). Both recombinant viruses stably expressed the corresponding SARS-CoV proteins, grew to similar end titres as the parental strain and induced high antibody titres against MV and the vectored SARS-CoV antigens (S and N) in transgenic mice susceptible to measles infection. The antibodies induced by rMV-S had a high neutralising effect on SARS-CoV as well as on MV. Moreover, significant N-specific cellular immune responses were measured by IFN-gamma ELISPOT assays. The pre-existence of anti-MV antibodies induced by the initial immunisation dose did not inhibit boost of anti-S and anti-N antibodies. Immunisations comprising a mixture of rMV-S and rMV-N induced immune responses similar in magnitude to that of vaccine components administered separately. These data support the suitability of MV as a bivalent candidate vaccine vector against MV and emerging viruses such as SARS-CoV.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003173 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003173 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:18346823
|texte= Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:18346823" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |